Published in Nat Rev Drug Discov on December 01, 2004
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum (2009) 3.34
Developments in the scientific understanding of lupus. Arthritis Res Ther (2008) 1.22
The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J Immunol (2009) 1.17
Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis (2012) 1.08
Gene-expression profiling in rheumatic disease: tools and therapeutic potential. Nat Rev Rheumatol (2009) 0.89
Peroxisome proliferator-activated receptor gamma agonists in the prevention and treatment of murine systemic lupus erythematosus. Immunology (2014) 0.85
Serum growth arrest-specific protein 6 levels are a reliable biomarker of disease activity in systemic lupus erythematosus. J Clin Immunol (2012) 0.84
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. Arthritis Rheumatol (2017) 0.82
Belimumab in systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis (2012) 0.80
Biomarkers as tools for improved diagnostic and therapeutic monitoring in systemic lupus erythematosis. Arthritis Res Ther (2009) 0.78
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med (2005) 5.50
Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med (2015) 3.63
The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.05
Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation (2008) 2.54
Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events. Arthritis Rheum (2003) 2.19
Myocardial-tissue-specific phenotype of maternal microchimerism in neonatal lupus congenital heart block. Lancet (2003) 2.13
Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken) (2013) 2.13
Sex ratios among children of lupus pregnancies. Arthritis Rheum (2013) 1.98
Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest (2006) 1.76
Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum (2004) 1.76
Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost (2005) 1.73
Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation (2011) 1.68
Genetic association of cutaneous neonatal lupus with HLA class II and tumor necrosis factor alpha: implications for pathogenesis. Arthritis Rheum (2004) 1.67
Shedding of endothelial protein C receptor contributes to vasculopathy and renal injury in lupus: in vivo and in vitro evidence. Kidney Int (2005) 1.66
Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum (2008) 1.65
Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum (2006) 1.53
Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum (2010) 1.52
A central role of plasmin in cardiac injury initiated by fetal exposure to maternal anti-Ro autoantibodies. Rheumatology (Oxford) (2013) 1.41
Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus. Curr Rheumatol Rep (2007) 1.36
Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum (2009) 1.32
Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. Arthritis Rheum (2005) 1.27
Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block. J Immunol (2010) 1.26
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation (2012) 1.20
Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis (2010) 1.19
Transdifferentiation of cardiac fibroblasts, a fetal factor in anti-SSA/Ro-SSB/La antibody-mediated congenital heart block. J Immunol (2002) 1.18
Cytokine polymorphisms and histologic expression in autopsy studies: contribution of TNF-alpha and TGF-beta 1 to the pathogenesis of autoimmune-associated congenital heart block. J Immunol (2003) 1.17
Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus. Arthritis Rheum (2010) 1.13
Neonatal lupus syndromes. Rheum Dis Clin North Am (2007) 1.11
Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol (2009) 1.10
The optimal tool for assessment of organ damage in antiphospholipid syndrome. J Rheumatol (2013) 1.07
Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum (2010) 1.06
Congenital heart block: identification of autoantibody binding site on the extracellular loop (domain I, S5-S6) of alpha(1D) L-type Ca channel. J Autoimmun (2009) 1.06
Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. Rheumatology (Oxford) (2012) 1.06
Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev (2013) 1.04
A novel role of endothelin-1 in linking Toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block. J Biol Chem (2011) 1.03
Catastrophic antiphospholipid syndrome. J Intensive Care Med (2006) 1.02
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum (2004) 1.01
Ro60 requires Y3 RNA for cell surface exposure and inflammation associated with cardiac manifestations of neonatal lupus. J Immunol (2013) 1.00
Binding of anti-SSA antibodies to apoptotic fetal cardiocytes stimulates urokinase plasminogen activator (uPA)/uPA receptor-dependent activation of TGF-β and potentiates fibrosis. J Immunol (2011) 0.98
Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum (2012) 0.98
Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol (2002) 0.97
Role of hypoxia and cAMP in the transdifferentiation of human fetal cardiac fibroblasts: implications for progression to scarring in autoimmune-associated congenital heart block. Arthritis Rheum (2007) 0.96
The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol (2007) 0.95
Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective. Indian J Pediatr (2002) 0.94
Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. Arthritis Rheum (2008) 0.94
Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum (2008) 0.94
Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. Arthritis Rheum (2002) 0.94
Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease. Ther Adv Musculoskelet Dis (2013) 0.94
Subcellular redistribution of la/SSB autoantigen during physiologic apoptosis in the fetal mouse heart and conduction system: a clue to the pathogenesis of congenital heart block. Arthritis Rheum (2002) 0.93
Brief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus. Arthritis Rheum (2012) 0.92
β2-glycoprotein I and protection from anti-SSA/Ro60-associated cardiac manifestations of neonatal lupus. J Immunol (2011) 0.92
Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis (2007) 0.91
The role of biomarkers in the assessment of lupus. Best Pract Res Clin Rheumatol (2005) 0.91
Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand? Curr Rheumatol Rep (2011) 0.91
Lupus and thrombosis. J Rheumatol (2006) 0.90
Exposure and binding of selected immunodominant La/SSB epitopes on human apoptotic cells. Arthritis Rheum (2005) 0.90
Birth order, gender and recurrence rate in autoantibody-associated congenital heart block: implications for pathogenesis and family counseling. Lupus (2003) 0.90
Churg-strauss syndrome with eosinophilic myocarditis: a clinical pathology conference held by the division of rheumatology at hospital for special surgery. HSS J (2012) 0.89
Antiphospholipid syndrome. Prog Cardiovasc Dis (2009) 0.89
Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. J Rheumatol (2009) 0.89
Cardiac manifestations in the antiphospholipid syndrome. Rheum Dis Clin North Am (2006) 0.88
Complement receptor 3 influences toll-like receptor 7/8-dependent inflammation: implications for autoimmune diseases characterized by antibody reactivity to ribonucleoproteins. J Biol Chem (2013) 0.88
Autoantibodies against the serotoninergic 5-HT4 receptor and congenital heart block: a reassessment. J Autoimmun (2005) 0.88
Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse. Clin Rev Allergy Immunol (2009) 0.87
Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. Rheumatology (Oxford) (2009) 0.87
Perioperative management of antiphospholipid antibody-positive patients. Curr Rheumatol Rep (2014) 0.87
Autoimmune-associated congenital heart block: dissecting the cascade from immunologic insult to relentless fibrosis. Anat Rec A Discov Mol Cell Evol Biol (2004) 0.86
Pregnancy outcomes following total hip arthroplasty: a preliminary study and review of the literature. Orthopedics (2003) 0.86
Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus. Arthritis Care Res (Hoboken) (2012) 0.86
Warfarin in antiphospholipid syndrome--time to explore new horizons. J Rheumatol (2005) 0.86
Clinical assessment and management of cytopenias in lupus patients. Curr Rheumatol Rep (2011) 0.85
Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group. Am J Med (2011) 0.85
Intravenous immunoglobulin and placental transport of anti-Ro/La antibodies: comment on the letter by Kaaja and Julkunen. Arthritis Rheum (2004) 0.85
Rituximab: wanted dead or alive... Arthritis Rheum (2010) 0.84
Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum (2006) 0.84
Identifying an early marker for congenital heart block: when is a long PR interval too long? Comment on the article by Sonesson et al. Arthritis Rheum (2005) 0.84
Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry. Pediatrics (2002) 0.84
Long-term followup of children with neonatal lupus and their unaffected siblings. Arthritis Rheum (2002) 0.84
Clearance of apoptotic cells: TGF-beta in the balance between inflammation and fibrosis. J Leukoc Biol (2003) 0.84
Cardiac manifestations of neonatal lupus: a review of autoantibody-associated congenital heart block and its impact in an adult population. Cardiol Rev (2012) 0.84
More to death than dying: apoptosis in the pathogenesis of SSA/Ro-SSB/La-associated congenital heart block. Rheum Dis Clin North Am (2004) 0.83
Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines? J Rheumatol (2002) 0.83
Estrogens and lupus: bubbling cauldron or another overrated Witches' Brew? Arthritis Rheum (2007) 0.82
Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin Thromb Hemost (2008) 0.82
Antibody reactivity to alpha-enolase in mothers of children with congenital heart block. J Rheumatol (2009) 0.82
Autoimmunity as a result of escape from RNA surveillance. J Immunol (2006) 0.81
Current therapies for lupus nephritis in an ethnically heterogeneous cohort. J Rheumatol (2009) 0.81
Belimumab in systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis (2012) 0.80
Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease. Curr Opin Rheumatol (2012) 0.80
Treatment of the antiphospholipid syndrome. N Engl J Med (2003) 0.79
Tumor-induced osteomalacia. Clin Rheumatol (2007) 0.79
Clinical causes and treatment of the thrombotic storm. Expert Rev Hematol (2012) 0.79
The challenge of bleeding in antiphospholipid antibody-positive patients. Curr Rheumatol Rep (2015) 0.79
Cognitive dysfunction in antiphospholipid antibody (aPL)-negative systemic lupus erythematosus (SLE) versus aPL-positive non-SLE patients. Clin Exp Rheumatol (2013) 0.78
Does the cellular localization of antigens in or on apoptotic blebs influence the pathogenicity or benefit of cognate antibodies? Comment on the article by Dieudé et al. Arthritis Rheum (2003) 0.78